Abstract
Summary
An ultrafiltration screening technique was used to determine the effectiveness of desferrioxamine B-methane sulfonate (DFOM), a therapeutic agent that forms complexes with ferrous and ferric iron, in binding plutonium under physiological conditions. Although DFOM increased the fraction of plutonium ultrafilterable from blood plasma, the only effects when given intra-peritoneally to plutonium-poisoned mice were the prevention of further uptake of plutonium in the bone after initiation of therapy and a small rise in urinary plutonium.
Get full access to this article
View all access options for this article.